Neumora Therapeutics Inc (NMRA)

Currency in USD
1.46
-0.19(-11.52%)
Closed·
After Hours
1.50+0.04(+2.74%)
·
NMRA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
NMRA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.431.69
52 wk Range
0.6117.19
Key Statistics
Prev. Close
1.65
Open
1.65
Day's Range
1.43-1.69
52 wk Range
0.61-17.19
Volume
800.19K
Average Volume (3m)
1.5M
1-Year Change
-87.01%
Book Value / Share
1.41
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
NMRA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.05
Upside
+314.61%
Members' Sentiments
Bearish
Bullish
ProTips
3 analysts have revised their earnings upwards for the upcoming period

Neumora Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Neumora Therapeutics Inc Company Profile

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer’s disease. In addition, the company’s preclinical phase product includes NMRA-NMDA and NMRA-M4R for the treatment of Schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson’s disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Neumora Therapeutics Inc SWOT Analysis


Navacaprant Setback
Neumora's lead drug for major depressive disorder faces challenges after KOSTAL-1 trial failure, prompting reevaluation of its $2.2 billion peak sales forecast
Pipeline Potential
Explore Neumora's diverse neuroscience portfolio targeting bipolar depression, schizophrenia, and Alzheimer's-related agitation, offering multiple growth avenues
Financial Health
Despite strong cash reserves, Neumora grapples with negative free cash flow and high debt, presenting a complex financial picture for investors
Market Outlook
Analysts maintain cautious optimism with price targets ranging from $7 to $29, reflecting the uncertain yet potentially lucrative neuroscience market
Read full SWOT analysis

Neumora Therapeutics Inc Earnings Call Summary for Q2/2025

  • Neumora Therapeutics beats Q2 2025 EPS estimates with -$0.33 vs -$0.45 forecast, despite 4.22% stock decline in aftermarket trading
  • Net loss reduced to $52.7M from $58.7M YoY; strong cash position of $217.6M supports operations into 2027
  • Multiple clinical trials underway with significant data readouts expected in next 18 months, including NMRA-215 and NMRA-861
  • CEO highlights potential of NLRP3 inhibition for obesity treatment, emphasizing innovative approach to health challenges
  • Company remains focused on core programs, prioritizing resources for most impactful developments amid continued net losses
Last Updated: 07/08/2025, 08:36
Read Full Transcript

Compare NMRA to Peers and Sector

Metrics to compare
NMRA
Peers
Sector
Relationship
P/E Ratio
−0.9x−3.8x−0.5x
PEG Ratio
−0.040.020.00
Price/Book
1.3x3.5x2.6x
Price / LTM Sales
-2.1x3.3x
Upside (Analyst Target)
208.2%69.2%43.5%
Fair Value Upside
Unlock5.9%6.8%Unlock

Analyst Ratings

3 Buy
5 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 6.05
(+314.61% Upside)

Earnings

Latest Release
Aug 06, 2025
EPS / Forecast
-0.33 / -0.45
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

NMRA Income Statement

People Also Watch

18.23
SRPT
+1.50%
2.070
VOR
0.00%
2.56
INMB
-8.24%
51.43
BMNR
+24.59%

FAQ

What Stock Exchange Does Neumora Therapeutics Trade On?

Neumora Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Neumora Therapeutics?

The stock symbol for Neumora Therapeutics is "NMRA."

What Is the Neumora Therapeutics Market Cap?

As of today, Neumora Therapeutics market cap is 236.15M.

What Is Neumora Therapeutics's Earnings Per Share (TTM)?

The Neumora Therapeutics EPS (TTM) is -1.57.

When Is the Next Neumora Therapeutics Earnings Date?

Neumora Therapeutics will release its next earnings report on 28 Oct 2025.

From a Technical Analysis Perspective, Is NMRA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Neumora Therapeutics Stock Split?

Neumora Therapeutics has split 0 times.

How Many Employees Does Neumora Therapeutics Have?

Neumora Therapeutics has 103 employees.

What is the current trading status of Neumora Therapeutics (NMRA)?

As of 09 Aug 2025, Neumora Therapeutics (NMRA) is trading at a price of 1.46, with a previous close of 1.65. The stock has fluctuated within a day range of 1.43 to 1.69, while its 52-week range spans from 0.61 to 17.19.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.